Advertisement
 
YOU ARE HERE: LAT HomeCollectionsNon Hodgkin S Lymphoma
IN THE NEWS

Non Hodgkin S Lymphoma

FEATURED ARTICLES
BUSINESS
February 1, 1999 | PAUL JACOBS
Tobacco plants may provide a new way of treating non-Hodgkin's lymphoma, a cancer that will strike an estimated 56,800 Americans this year. Scientists at Stanford University and Biosource Technologies are developing a customized lymphoma vaccine produced in tobacco plants that are being grown indoors at the biotechnology company's Vacaville, Calif., facility. The most common form of non-Hodgkin's lymphoma affects cells that produce antibodies to infectious disease.
ARTICLES BY DATE
BUSINESS
August 18, 2005 | From Reuters
Genentech Inc., Swiss drug maker Roche Holding and Biogen Idec Inc. said they had completed their U.S. marketing application to expand use of their drug Rituxan to patients never before treated for non-Hodgkin's lymphoma. The popular medicine was approved in the United States in 1997 for patients with the low-grade form of that type of lymphoma who had failed to benefit from other standard therapies.
Advertisement
NEWS
March 30, 1990
Three Colombians convicted of possessing 1,200 pounds of cocaine for sale in the largest drug bust in the history of the Glendale Police Department were sentenced Thursday to a combined 41 years in state prison. Superior Court Judge Gordon Ringer sentenced Adolfo Guevara, 28, to 19 years; Ferney Tavera, 25, to 12 years, and Luis Varcla, 26, to 10 years. Ana Agudelo, 72, also a Colombian, was placed on six months' probation, said Deputy Dist. Atty. Ellen Berk.
BUSINESS
September 19, 2000 | Times Staff and Dow Jones
Tustin biotech company Techniclone Corp. and Berlex Laboratories Inc. said Monday that they have begun the first phase of their study of Oncolym, a Techniclone drug to treat non-Hodgkin's lymphoma. The companies said in a press release that the study will determine the highest tolerated single dose of Oncolym to maximize the product's therapeutic potential. The study is designed to treat as many as 18 patients, with provision to treat more if necessary.
BUSINESS
November 22, 1999 | PAUL JACOBS, TIMES STAFF WRITER
Imagine an anti-cancer drug that acts like a guided missile, seeking out a patient's malignant cells and then destroying them with microscopic radioactive warheads, while sparing the surrounding healthy tissue. Such an approach to battling cancer was first envisioned a quarter of a century ago with the discovery of a way to make large amounts of highly specific antibodies, natural substances that travel through the bloodstream and can seek out targets on the surface of tumors.
NEWS
February 11, 1994 | Reuters
Former First Lady Jacqueline Kennedy Onassis has non-Hodgkin's lymphoma, a treatable form of cancer of the lymphatic system, and has been undergoing chemotherapy for about a month, the New York Times reported in today's editions. The paper said Onassis, 64, had not interrupted her personal routines or her duties as a book editor.
BUSINESS
August 18, 2005 | From Reuters
Genentech Inc., Swiss drug maker Roche Holding and Biogen Idec Inc. said they had completed their U.S. marketing application to expand use of their drug Rituxan to patients never before treated for non-Hodgkin's lymphoma. The popular medicine was approved in the United States in 1997 for patients with the low-grade form of that type of lymphoma who had failed to benefit from other standard therapies.
CALIFORNIA | LOCAL
June 3, 1996 | MICHAEL G. WAGNER, TIMES STAFF WRITER
Chris Beck was a typical 19-year-old college kid struggling to keep his grades up when he went to a doctor to have a couple of small bumps on his head examined. The doctor told him they were impacted hair follicles, nothing to worry about. So on Jan. 23, he had them surgically removed. The bumps turned out to be cancer, non-Hodgkin's lymphoma, a form of the disease that causes cells in the immune system to spin out of control, create tumors and dispatch them throughout the body.
BUSINESS
October 21, 1998 | (Bloomberg News)
Coulter Pharmaceutical Inc.'s Bexxar drug could be a breakthrough therapy for low-grade non-Hodgkin's lymphoma, said analysts whom the company briefed on late-stage clinical trials of the medication.
NEWS
April 16, 1994 | Associated Press
Jacqueline Kennedy Onassis, who is suffering from cancer of the lymph system, has been hospitalized for treatment. "She is expected to be here for several days," said Myrna Manners, a spokeswoman for New York Hospital-Cornell Medical Center. Manners would not say what kind of treatment the former First Lady was receiving or when she was admitted. Kennedy family spokeswoman Nancy Tuckerman did not return telephone calls Friday.
BUSINESS
November 22, 1999 | PAUL JACOBS, TIMES STAFF WRITER
Imagine an anti-cancer drug that acts like a guided missile, seeking out a patient's malignant cells and then destroying them with microscopic radioactive warheads, while sparing the surrounding healthy tissue. Such an approach to battling cancer was first envisioned a quarter of a century ago with the discovery of a way to make large amounts of highly specific antibodies, natural substances that travel through the bloodstream and can seek out targets on the surface of tumors.
BUSINESS
February 1, 1999 | PAUL JACOBS
Tobacco plants may provide a new way of treating non-Hodgkin's lymphoma, a cancer that will strike an estimated 56,800 Americans this year. Scientists at Stanford University and Biosource Technologies are developing a customized lymphoma vaccine produced in tobacco plants that are being grown indoors at the biotechnology company's Vacaville, Calif., facility. The most common form of non-Hodgkin's lymphoma affects cells that produce antibodies to infectious disease.
BUSINESS
October 21, 1998 | (Bloomberg News)
Coulter Pharmaceutical Inc.'s Bexxar drug could be a breakthrough therapy for low-grade non-Hodgkin's lymphoma, said analysts whom the company briefed on late-stage clinical trials of the medication.
CALIFORNIA | LOCAL
June 3, 1996 | MICHAEL G. WAGNER, TIMES STAFF WRITER
Chris Beck was a typical 19-year-old college kid struggling to keep his grades up when he went to a doctor to have a couple of small bumps on his head examined. The doctor told him they were impacted hair follicles, nothing to worry about. So on Jan. 23, he had them surgically removed. The bumps turned out to be cancer, non-Hodgkin's lymphoma, a form of the disease that causes cells in the immune system to spin out of control, create tumors and dispatch them throughout the body.
NEWS
April 16, 1994 | Associated Press
Jacqueline Kennedy Onassis, who is suffering from cancer of the lymph system, has been hospitalized for treatment. "She is expected to be here for several days," said Myrna Manners, a spokeswoman for New York Hospital-Cornell Medical Center. Manners would not say what kind of treatment the former First Lady was receiving or when she was admitted. Kennedy family spokeswoman Nancy Tuckerman did not return telephone calls Friday.
NEWS
February 11, 1994 | Reuters
Former First Lady Jacqueline Kennedy Onassis has non-Hodgkin's lymphoma, a treatable form of cancer of the lymphatic system, and has been undergoing chemotherapy for about a month, the New York Times reported in today's editions. The paper said Onassis, 64, had not interrupted her personal routines or her duties as a book editor.
BUSINESS
September 19, 2000 | Times Staff and Dow Jones
Tustin biotech company Techniclone Corp. and Berlex Laboratories Inc. said Monday that they have begun the first phase of their study of Oncolym, a Techniclone drug to treat non-Hodgkin's lymphoma. The companies said in a press release that the study will determine the highest tolerated single dose of Oncolym to maximize the product's therapeutic potential. The study is designed to treat as many as 18 patients, with provision to treat more if necessary.
BUSINESS
January 26, 2012 | By Tiffany Hsu
Biotech giant Amgen is hoping to bolster its cancer drug pipeline by buying fellow drug developer Micromet Inc. for $1.16 billion. At $11 a share, with an Amgen subsidiary buying the majority of Micromet's stock and then the Amgen parent company picking up the rest, the price represents a 33% premium on Micromet's closing price Wednesday. Thousand Oaks-based Amgen is itself among the world's premier drug makers but hasn't had many popular drugs in years. Rockville, Md.-based Micromet, meanwhile, is testing a promising treatment for leukemia and non-Hodgkin's lymphoma.
NEWS
March 30, 1990
Three Colombians convicted of possessing 1,200 pounds of cocaine for sale in the largest drug bust in the history of the Glendale Police Department were sentenced Thursday to a combined 41 years in state prison. Superior Court Judge Gordon Ringer sentenced Adolfo Guevara, 28, to 19 years; Ferney Tavera, 25, to 12 years, and Luis Varcla, 26, to 10 years. Ana Agudelo, 72, also a Colombian, was placed on six months' probation, said Deputy Dist. Atty. Ellen Berk.
Los Angeles Times Articles
|